Latest MHRA Yellow Card Adverse Reactions Reporting Scheme Data - Week 14/7/2021

Three COVID-19 vaccines - the Pfizer/BioNTech Vaccine, COVID-19 Vaccine AstraZeneca and COVID-19 Vaccine Moderna – are currently being used in the UK. All have been authorised for supply by the Medicines and Healthcare products Regulatory Agency (MHRA) following a thorough review of safety, quality and efficacy information from clinical trials. (THATS A BLATANT LIE - The injections are authorised for EMERGENCY USE ONLY)

At the time of this report, over 128,662 people across the UK are said to have died within 28 days of a positive test for coronavirus, however, the medical 'evidence' to confirm 'Death from Covid-19' is almost singularly non-existent, as doctors have been 'encouraged' to state Covid-19 as the cause of death without post-mortem analysis, their conclusion based purely on a PCR Test result, which as we know is no indicator of the presence of Covid-19.

'In clinical trials, the vaccines showed very high levels of protection against symptomatic infections with COVID-19. Data is now available on the impact of the vaccination campaign in reducing infections and illness in the UK'


As of 14 July 2021, for the UK, 91,567 Yellow Cards have been reported for the Pfizer/BioNTech vaccine, 222,291 have been reported for the COVID-19 Vaccine AstraZeneca, 10,109 for the COVID-19 Vaccine Moderna and 939 have been reported where the brand of the vaccine was not specified.

For the Pfizer/BioNTech, COVID-19 Vaccine AstraZeneca and COVID-19 Vaccine Moderna the overall reporting rate is around 3 to 7 Yellow Cards per 1,000 doses administered.

For all COVID-19 vaccines, the overwhelming majority of reports relate to injection-site reactions (sore arm for example) and generalised symptoms such as ‘flu-like’ illness, headache, chills, fatigue (tiredness), nausea (feeling sick), fever, dizziness, weakness, aching muscles, and rapid heartbeat. Generally, these happen shortly after the vaccination and are not associated with more serious or lasting illness.


Unfortunately the more serious Side Affects include:

  • Anaphylaxis (Severe allergic reactions) or anaphylactoid reactions

  • Bell’s Palsy

  • Thrombo-embolic events (Blood-clots) with concurrent low platelets

  • Capillary Leak Syndrome (CLS)

  • Menstrual disorders (period problems) and unexpected vaginal bleeding

  • Inflammation of the heart

  • Delayed hypersensitivity reactions

  • Cerebral venous sinus thrombosis (CVST)

  • Guillain-Barré Syndrome

  • Miller-Fisher Syndrome

  • Endocarditis

  • Myocarditis

  • Pericarditis

  • Temporal Association

  • Thrombocytopenia


Events with a fatal outcome

The MHRA has received 460 UK reports of suspected ADRs to the Pfizer/BioNTech vaccine in which the patient died shortly after vaccination, 999 reports for the COVID-19 Vaccine AstraZeneca, 7 for the COVID-19 Vaccine Moderna and 24 where the brand of vaccine was unspecified. The majority of these reports were in elderly people or people with underlying illness.


New advice Published


MHRA issues new advice, concluding a possible link between COVID-19 Vaccine AstraZeneca and extremely rare, unlikely to occur blood clots, (to date at least 70 people have died from the effects of clotting) but still maintain that the benefits of vaccination continue to outweigh any risks, but the MHRA advises careful consideration be given to people who are at higher risk of specific types of blood clots because of their medical condition.

  • The MHRA is not recommending age restrictions in COVID-19 Vaccine AstraZeneca vaccine use.

  • The MHRA’s scientific review of UK reports of extremely rare and unlikely to occur specific blood clots with lowered platelets has concluded that the evidence of a link with COVID-19 Vaccine AstraZeneca is stronger but more work is still needed.

  • By 31 March 20.2 million doses of the COVID-19 Vaccine AstraZeneca had been given in the UK meaning the overall risk of these blood clots is approximately 4 people in a million who receive the vaccine.

  • Anyone who did not have these side effects should come forward for their second dose when invited.

  • The data suggest there is a slightly higher incidence reported in the younger adult age groups and the MHRA advises that this evolving evidence should be taken into account when considering the use of the vaccine.

  • The MHRA is now issuing updated guidance for healthcare professionals on how to minimise risks, as well as further advice on symptoms for vaccine recipients to look out for 4 or more days after vaccination.

  • Vaccines are the best way to protect people from COVID-19 and have already saved thousands of lives. Everyone should continue to get their vaccination when asked to do so unless specifically advised otherwise.

JCVI advises on COVID-19 vaccine for people aged under 40


The Joint Committee on Vaccination and Immunisation (JCVI) has issued advice to the UK government on the use of the coronavirus (COVID-19) Oxford/AstraZeneca vaccine for people aged under 40.


The committee has reviewed the latest available evidence, including the current COVID-19 infection rate, the scale and pace of the vaccine programme and modelling of the timing and size of any third pandemic wave.

This has been considered alongside the latest advice from the Medicines and Healthcare products Regulatory Agency (MHRA) on extremely rare cases of concurrent thrombosis (blood clots) and thrombocytopenia (low platelet count) following the first dose of the Oxford/AstraZeneca vaccine.

The chances of a younger person becoming seriously ill with COVID-19 get smaller as infection rates increasingly come under control in the UK.

Considering this alongside the portfolio of vaccines available in the UK in the coming months and taking a precautionary approach in relation to the extremely small risk of thrombosis and thrombocytopenia following the first dose of the Oxford/AstraZeneca vaccine, the JCVI has advised a preference for adults aged 30 to 39 without underlying health conditions to receive an alternative to the Oxford/AstraZeneca vaccine – where available and only if this does not cause substantial delays in being vaccinated.

This follows the decision on 7 April to offer a preference for adults aged under 30.


The COVID-19 vaccines are highly effective and have been shown to substantially reduce the risk of death, severe disease and transmission of infection.

Yet the 'so called' vaccine can neither stop you catching Covid-19 again or passing it on. So what kind of useless treatment is it really?


As a precautionary measure, anyone who has the following symptoms from around 4 days to 4 weeks after vaccination is advised to seek prompt medical advice:

  • a severe headache that is not relieved with painkillers or is getting worse

  • a headache that feels worse when you lie down or bend over

  • a headache that is unusual for you and occurs with blurred vision, feeling or being sick, problems speaking, weakness, drowsiness or seizures

  • a rash that looks like small bruises or bleeding under the skin

  • shortness of breath, chest pain, leg swelling or persistent abdominal pain

This just demonstrates that the vaccine 'must be working'

3 views0 comments